BiotechTube

Certican® + Neoral + Myfortic + Simulect® + Corticosteroids

Phase 3Completed
1 views this week 0 watching⚡ Active
Interest: 40/100
40
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Renal Interstitial Fibrosis

Conditions

Renal Interstitial Fibrosis

Trial Timeline

Sep 1, 2009 → Jun 1, 2012

NCT ID
NCT01079143

About Certican® + Neoral + Myfortic + Simulect® + Corticosteroids

Certican® + Neoral + Myfortic + Simulect® + Corticosteroids is a phase 3 stage product being developed by Novartis for Renal Interstitial Fibrosis. The current trial status is completed. This product is registered under clinical trial identifier NCT01079143. Target conditions include Renal Interstitial Fibrosis.

What happened to similar drugs?

20 of 20 similar drugs in Renal Interstitial Fibrosis were approved

Approved (20) Terminated (0) Active (0)
✅tacrolimus + CellCept + steroids (methylprednisone or prednisone)Astellas PharmaApproved
✅Rituximab + Tacrolimus + Mycophenylate mofetil + Hydrocortisone + Prednisolone + PrednisoloneAstellas PharmaApproved
✅Tacrolimus, Prograf®Astellas PharmaApproved
✅Astagraf XL + Prograf + Mycophenolate mofetilAstellas PharmaApproved
✅Tacrolimus - Prograf® twice daily formulation + Tacrolimus - Advagraf® once daily formulationAstellas PharmaApproved
✅Tacrolimus + CyclosporineAstellas PharmaApproved
✅Tacrolimus sustained-release capsuleAstellas PharmaApproved

Hype Score Breakdown

Clinical
17
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT01079143Phase 3Completed

Competing Products

20 competing products in Renal Interstitial Fibrosis

See all competitors
ProductCompanyStageHype Score
MBX 2109 + MBX 2109 + MBX 2109 + MBX 2109MBX BiosciencesPhase 1
23
LY3473329Eli LillyPhase 1
29
Tildacerfont/PlaceboSpruce BiosciencesPhase 2
17
SPR001Spruce BiosciencesPhase 2
25
SPR001Spruce BiosciencesPhase 2
25
Tildacerfont/PlaceboSpruce BiosciencesPhase 2
17
TildacerfontSpruce BiosciencesPhase 2
17
Drotrecogin alfa activated (Xigris)Eli LillyPhase 2
35
LY3819469Eli LillyPhase 1
29
Atezolizumab + CabozantinibChugai PharmaceuticalPhase 3
32
DS-6000a + DS-6000aDaiichi SankyoPhase 1
33
DS-1093aDaiichi SankyoPhase 1
29
CS-3150Daiichi SankyoPhase 3
40
AGS-16C3FAstellas PharmaPhase 1
29
AGS-16M8FAstellas PharmaPhase 1
29
CP-461Astellas PharmaPhase 2
35
roxadustatAstellas PharmaPhase 3
40
YM178Astellas PharmaPhase 1
29
intravenous immunoglobulins (IVIG)Astellas PharmaPhase 1
29
bixalomerAstellas PharmaPre-clinical
26